NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
16.86
+0.38 (2.31%)
At close: Nov 20, 2024, 4:00 PM
17.08
+0.22 (1.30%)
Pre-market: Nov 21, 2024, 7:41 AM EST
NovoCure Revenue
NovoCure had revenue of $155.10M in the quarter ending September 30, 2024, with 21.81% growth. This brings the company's revenue in the last twelve months to $577.74M, up 14.63% year-over-year. In the year 2023, NovoCure had annual revenue of $509.34M, down -5.30%.
Revenue (ttm)
$577.74M
Revenue Growth
+14.63%
P/S Ratio
3.14
Revenue / Employee
$397,617
Employees
1,453
Market Cap
1.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.66M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | 351.32M | 103.25M | 41.62% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Patterson Companies | 6.53B |
| Integra LifeSciences Holdings | 1.56B |
| Evotec SE | 866.67M |
| Harmony Biosciences Holdings | 681.88M |
| AtriCure | 447.57M |
| Tarsus Pharmaceuticals | 129.62M |
| RxSight | 128.29M |
| NewAmsterdam Pharma Company | 33.59M |
NVCR News
- 21 days ago - NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 22 days ago - Novocure Appoints Christoph Brackmann as Chief Financial Officer - Business Wire
- 22 days ago - Novocure Reports Third Quarter 2024 Financial Results - Business Wire
- 5 weeks ago - NovoCure: There Is Still More Upside - Seeking Alpha
- 5 weeks ago - FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients - Benzinga
- 5 weeks ago - FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer - Business Wire
- 7 weeks ago - Novocure to Report Third Quarter 2024 Financial Results - Business Wire
- 2 months ago - Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy - Business Wire